Winton Group’s Edgewise Therapeutics EWTX Stock Holding History

Winton Group’s Portfolio EWTX Stock Details EWTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-14,184	Closed	-$352K	–	1193
2025 Q4	$352K	Buy	+14,184	New	+$285K	0.01%	713

Other funds holding EWTX

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Janus Henderson Group

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Winton Group's EWTX Position: Q1 2026 in Review

Winton Group sold out of Edgewise Therapeutics (EWTX) in Q1 2026, closing a stake of 14,184 shares — an estimated $352K sold.

Winton Group first reported a position in EWTX in Q4 2025 and held it in 1 quarter. The position peaked at $352K in Q4 2025. 214 funds tracked by Wall St. Rank hold EWTX as of Q1 2026.

Winton Group reported no remaining Edgewise Therapeutics position as of Q1 2026 after selling out during the quarter.
Winton Group sold 14,184 Edgewise Therapeutics shares in Q1 2026, an estimated $352K.
Winton Group first reported a position in Edgewise Therapeutics in Q4 2025 and held it in 1 quarter.
Winton Group's Edgewise Therapeutics position peaked at $352K in Q4 2025.
214 funds tracked by Wall St. Rank held Edgewise Therapeutics as of Q1 2026.

Based on Winton Group's 13F filing for Q1 2026, filed 12 May 2026.